| |
Explore how oncology developers are adapting to a highly competitive and uncertain oncology therapeutic landscape.
|
|
Today’s Big NewsOct 29, 2024 |
|
Wednesday, November 13 , 2024 | 10am ET / 7am PT Join industry experts to gain insights pertinent to efficient and effective drug development. Understand and execute a risk-based critical thinking approach related to injectable drug packaging and delivery. Register now.
|
|
| By Angus Liu Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. The drug will face a couple of challenges as Novartis works to reach more patients in the setting. |
|
|
|
By James Waldron Not content with getting the first lupus drug to market in the form of the blockbuster Benlysta, GSK is handing over $300 million in upfront cash for a clinical-stage T-cell engager it believes could target patients who aren’t benefiting from current treatments. |
By Conor Hale Since rolling out its pulsed field ablation system for treating atrial fibrillation earlier this year, Boston Scientific has seen its Farapulse sales grow by leaps and bounds. |
By Kevin Dunleavy Eli Lilly looks to tweak the dosing regimen of its Alzheimer’s disease drug Kisunla after showing reduced side effect of brain swelling in a phase 3 trial. |
|
Tuesday, November 12, 2024 | 2pm ET / 11am PT Major breakthroughs have been made recently in the research and development of Alzheimer’s disease. With a stronger understanding of disease pathology, new therapeutic pathways and the launch of the first disease-modifying treatments, join us to learn more about what the future holds in Alzheimer’s disease therapeutic development. Register now.
|
|
By Nick Paul Taylor Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years. |
By James Waldron Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession. |
By Fraiser Kansteiner In a phase 3 bridging study run by Zai Lab in China, Bristol Myers Squibb's KarXT helped schizophrenia patients chart a 9.2-point total-score reduction on the Positive and Negative Syndrome Scale versus placebo at Week 5, teeing up a forthcoming regulatory filing. |
By Zoey Becker The company is projecting yearly sales of $61 billion to $64 billion in a $1.5 billion boost from previous forecasts. |
By Conor Hale WASHINGTON, D.C.—The company’s Diamondback 360 system is designed to etch away at the inside of severely calcified lesions, where hardened plaques can make it difficult to fully inflate a balloon or optimally expand a stent. |
By Darren Incorvaia As its lead gene therapy flows toward the clinic, Purespring Therapeutics is uncorking new preclinical data showing the candidate reduced kidney scarring and fibrosis in mice and safely delivered a gene to pig kidneys. |
By Angus Liu Novartis didn't use a priority review voucher for Pluvicto's key application in an earlier treatment setting for prostate cancer. The company made the decision in response to the FDA's request for "flexibility" in its review timeline, Novartis CEO Vas Narasimhan explained. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
